Evidence for systems that carry regulated work.
The July release carries bug fixes and sits inside a broader transition toward structured application data, new MAA forms, and mandatory PLM web-based eAF use for centrally authorised product variations.
The July package refresh adds forward-compatibility samples and revises regional vocabulary, conformance, and transmission materials for a standard FDA already accepts for new applications.
The June release expands access to structured medicinal-product data while marketing authorisation holders face staged manufacturer and pack-data enrichment deadlines.
The July package refresh adds forward-compatibility samples and revises regional vocabulary, conformance, and transmission materials for a standard FDA already accepts for new applications.
The June release expands access to structured medicinal-product data while marketing authorisation holders face staged manufacturer and pack-data enrichment deadlines.
The transition moves actor, device, certificate, and market-surveillance records from voluntary use into required EU operating workflows, increasing the cost of disconnected regulatory data.
The February guidance focuses assurance effort on software risk and confidence rather than prescribing one validation-document package, giving buyers a sharper way to examine vendor evidence and intended use.
The rule now incorporates ISO 13485:2016 by reference and replaces QSIT with a new inspection process, shifting the questions device manufacturers should ask of quality systems and evidence.
The January transition changes classification and procedure rules for post-authorisation changes, forcing regulatory operations teams to align systems, forms, content, and implementation dates.
Electronic quality systems coordinate controlled documents, training, events, CAPA, change, audits, suppliers, complaints, and management review without becoming the quality system themselves.
Read the market record →Regulatory information management connects structured product records with activities, registrations, dossiers, correspondence, commitments, and post-approval change.
Read the market record →Buyers need version-specific evidence, configuration accountability, controlled change, traceability, and a clear line between provider deliverables and customer responsibility.
Read the market record →A product or process change may affect quality events, regulatory commitments, submissions, labeling, training, supplier records, and inspection evidence. Architecture matters at the handoffs.
Read the market record →Regulatory operations teams need controlled form-version selection, documented transition dates, testing, and reconciliation with PMS and PLM eAF workflows.
Sponsors and regulatory operations teams should recheck supported package versions, controlled vocabulary, technical validation, release timing, and internal change-assessment evidence.
The release increases the testability and reuse of some authority product data but does not remove the need for internal master-data ownership, reconciliation, and controlled regulatory workflows.
Medical-device organizations need controlled data ownership and change propagation across quality, product, certificate, operator, and regulatory records.
Buyers should evaluate intended-use, risk, supplier evidence, testing, change control, and customer responsibilities instead of relying on an unbounded validated-software claim.
Device manufacturers must align their controlled quality systems and inspection evidence; software alignment can support but cannot establish organizational compliance.
The research connects the provider market, normalized capabilities, authority records, operating domains, and source limitations rather than presenting a score or universal winner.
Read the report →